Annexon has completed enrollment in its phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

KIO-104 is for the treatment of a wide range of ocular diseases, including ocular inflammation, uveitis, age-related macular ...

At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization ...

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ...

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Funding will be specifically used to accelerate the clinical development of urcosimod (formerly called OK-101).

Pinguecula is a benign, common degeneration of the conjunctiva that appears as a grey-white-yellow mass on the bulbar ...

Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other ...